ClinicalTrials.gg
CompletedNCT04005716Updated Feb 28, 2025Results posted

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

A Phase 3 interventional study of Tislelizumab and Cisplatin in Small Cell Lung Cancer, sponsored by BeiGene. Completed at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing tislelizumab in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, none of them phase 3. tislelizumab · Small Cell Lung Carcinoma.

Enrollment
Largest of 14
457 · median 34
Started
2019
the only one that year
Phase 3
Only one
of the 14
Registered
1st of 14
by date
Lead sponsor
1 of 14
BeiGene

Among the 14 studies testing tislelizumab in Small Cell Lung Carcinoma, this one has the largest enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 1st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 14 studies testing tislelizumab in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tislelizumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This Phase 3 study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of tislelizumab in combination with either cisplatin or carboplatin and etoposide (Arm A), compared to placebo combined with either cisplatin or carboplatin and etoposide (Arm B), as a first-line treatment for participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age≥18 years old, male or female, signed Form (ICF).
  2. (ECOG) performance status of 0 or 1
  3. or cytologically confirmed ES-SCLC
  4. No prior systemic treatment for ES-SCLC
  5. Adequate hematologic and end organ function

Key Exclusion Criteria:

  1. Active or uncontrolled, untreated ;
  2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;
  3. Was administered a ≤ 4 weeks before randomization;
  4. Active diseases or history of autoimmune diseases that may relapse
  5. Any condition that required systemic treatment with either or other medication ≤ 14 days before randomization;
  6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;
  7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to randomization, including but not limited to tuberculosis infection;
  8. Participant with untreated virus (HBV)/ virus (HCV), or a known history of infection;
  9. Participants with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized at the time of randomization;
  10. pericardial effusion, or Clinically uncontrolled pleural effusion

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    Arm A: Tislelizumab + Chemotherapy

    Participants received tislelizumab in combination with either cisplatin or carboplatin (at the investigator's discretion) and etoposide during the induction phase, administered every 3 weeks for 4 cycles. Upon completion of the induction phase, participants transitioned to maintenance therapy with tislelizumab only, administered once every 3 weeks.

    Drug: Tislelizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Etoposide

  • Placebo comparator
    Arm B: Placebo + Chemotherapy

    Participants received a placebo in combination with either cisplatin or carboplatin (at the investigator's discretion) and etoposide during the induction phase, given every 3 weeks for 4 cycles. Upon completion of the induction phase, participants transitioned to maintenance therapy with placebo only, administered once every 3 weeks.

    Drug: Cisplatin · Drug: Carboplatin · Drug: Etoposide · Drug: Placebo

Interventions

  • 200 mg administered intravenously on Day 1 of each 21-day cycle

  • 75 mg/m² was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of two hours. Treatment with cisplatin was discontinued starting in Cycle 5 and beyond.

  • An area under the curve (AUC) of 5 mg/mL/min was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of 15 to 60 minutes. Treatment with carboplatin was discontinued starting in Cycle 5 and beyond.

  • 100 mg/m² was administered intravenously from Day 1 to Day 3 of each 21-day cycle, infused over a duration of 60 minutes. Treatment with etoposide was discontinued starting in Cycle 5 and beyond.

  • DrugPlacebo

    200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS. Progressive Disease (PD): At least a 20% increase in the size of target lesions, with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

  2. Overall Response Rate (ORR)

    Orr is defined as the percentage of participants who had partial response or complete response as determined by the investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions with no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

  3. Disease Control Rate (DCR)

    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1. Stable Disease: Neither sufficient shrinkage of target lesions to qualify for PR nor sufficient increase to qualify for progressive disease, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, and no new lesions.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

  4. Clinical Benefit Rate (CBR)

    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or durable stable disease (stable disease for at least 24 weeks) per RECIST v1.1.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

  5. Duration of Response (DOR)

    Defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator per RECIST v1.1, or death from any cause, whichever comes first. Median DOR was estimated using Kaplan-Meier methodology.

    Time frame: From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

  6. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: From the first dose to 30 days after the last dose or final cutoff on December 29, 2023, maximum treatment exposure was 232 weeks for Arm A and 157 weeks for Arm B.

  7. Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status and Physical Function Score.

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Baseline to Cycles 4 and 6 ( Each cycle was 21 days)

  8. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) Symptom Scores

    Change from baseline in EORTC QLQ-CL13 scores for coughing, dysphagia, and chest pain. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

    Time frame: Baseline to Cycles 4 and 6 ( Each cycle was 21 days)

  9. Time to Deterioration (TTD)

    Time to deterioration is defined as the time from randomization to the first confirmed worsening score or death. Clinically meaningful deterioration is defined as a ≥10-point decrease from baseline in QLQ-C30 physical functioning and a ≥10-point increase in QLQ-LC13 coughing and chest pain scores. If a participant did not have an event (death or deterioration), they were censored at their last clinic visit at which corresponding score was measured. Median TTD was estimated using Kaplan-Meier methodology.

    Time frame: From randomization to the primary completion data cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.

07

Results

Posted Feb 28, 2025

Participant flow

Participants were enrolled across multiple study centers in China. The first participant was randomized on July 22, 2019, and the last participant completed the study on December 29, 2023.

Participant flow — Overall Study
MilestoneArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Started227230
Treated227229
Completed4926
Not completed178204
Withdrew: Death175196
Withdrew: Withdrawal by subject16
Withdrew: Lost to follow-up22

Outcome measures

PrimaryOverall Survival (OS)

Defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Overall Survival (OS)15.5 (13.5 to 17.1)13.5 (12.1 to 14.9)
Statistical analysis
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Log Rank · p = 0.0040 · Hazard ratio (hr): 0.75 · 95% CI 0.61 to 0.93The hazard ratio was estimated using a stratified Cox regression model with Efron's method for ties, stratified by ECOG performance status and investigator-selected platinum agents, with Arm B as the reference group.
SecondaryProgression Free Survival (PFS)

Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS. Progressive Disease (PD): At least a 20% increase in the size of target lesions, with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Progression Free Survival (PFS)4.7 (4.3 to 5.5)4.3 (4.2 to 4.4)
Statistical analysis
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.64 · 95% CI 0.52 to 0.78The hazard ratio was estimated using a stratified Cox regression model with Efron's method for ties, stratified by ECOG performance status and investigator-selected platinum agents, with Arm B as the reference group.
SecondaryOverall Response Rate (ORR)

Orr is defined as the percentage of participants who had partial response or complete response as determined by the investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions with no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Overall Response Rate (ORR)68.3 (61.8 to 74.3)61.7 (55.1 to 68.0)
Statistical analysis
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Odds ratio (or): 1.33 · 95% CI 0.90 to 1.96Odds ratio was calculated using Cochran-Mantel-Haenszel estimates and stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin)
SecondaryDisease Control Rate (DCR)

Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1. Stable Disease: Neither sufficient shrinkage of target lesions to qualify for PR nor sufficient increase to qualify for progressive disease, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, and no new lesions.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Disease Control Rate (DCR)88.5 (83.7 to 92.4)88.3 (83.4 to 92.1)
SecondaryClinical Benefit Rate (CBR)

Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or durable stable disease (stable disease for at least 24 weeks) per RECIST v1.1.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Clinical Benefit Rate (CBR)69.2 (62.7 to 75.1)65.2 (58.7 to 71.4)
SecondaryDuration of Response (DOR)

Defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator per RECIST v1.1, or death from any cause, whichever comes first. Median DOR was estimated using Kaplan-Meier methodology.

Time frame:
From randomization to the primary completion cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Median · Months
Duration of Response (DOR)
MonthsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Duration of Response (DOR)4.3 (4.1 to 5.6)3.7 (3.0 to 4.1)
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

Time frame:
From the first dose to 30 days after the last dose or final cutoff on December 29, 2023, maximum treatment exposure was 232 weeks for Arm A and 157 weeks for Arm B.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
TEAEs226228
SAEs9470
SecondaryChange From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status and Physical Function Score.

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Time frame:
Baseline to Cycles 4 and 6 ( Each cycle was 21 days)
Reported as:
Mean · Score on a scale
Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status and Physical Function Score.
Score on a scaleArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Global Health Status/Quality of Life (Cycle 4)8.9 ± 22.794.5 ± 19.46
Global Health Status/Quality of Life (Cycle 6)11.3 ± 21.304.2 ± 19.04
Physical Functioning (Cycle 4)0.6 ± 14.820.4 ± 14.57
Physical Functioning (Cycle 6)1.9 ± 15.181.8 ± 12.36
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) Symptom Scores

Change from baseline in EORTC QLQ-CL13 scores for coughing, dysphagia, and chest pain. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

Time frame:
Baseline to Cycles 4 and 6 ( Each cycle was 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) Symptom Scores
score on a scaleArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
Coughing (Cycle 4)-19.5 ± 26.58-16.0 ± 22.85
Coughing (Cycle 6)-18.6 ± 27.86-16.7 ± 25.08
Dysphagia (Cycle 4)-2.5 ± 12.12-3.1 ± 14.72
Dysphagia (Cycle 6)-2.9 ± 11.47-3.5 ± 15.23
Chest Pain (Cycle 4)-7.5 ± 22.65-5.9 ± 20.97
Chest Pain (Cycle 6)-7.0 ± 25.34-6.9 ± 21.51
SecondaryTime to Deterioration (TTD)

Time to deterioration is defined as the time from randomization to the first confirmed worsening score or death. Clinically meaningful deterioration is defined as a ≥10-point decrease from baseline in QLQ-C30 physical functioning and a ≥10-point increase in QLQ-LC13 coughing and chest pain scores. If a participant did not have an event (death or deterioration), they were censored at their last clinic visit at which corresponding score was measured. Median TTD was estimated using Kaplan-Meier methodology.

Time frame:
From randomization to the primary completion data cut-off on April 19, 2023, the median follow-up was 15.44 months (range: 0.2-44.9) for Arm A and 13.22 months (range: 0.1-40.8) for Arm B.
Reported as:
Median · Months
Time to Deterioration (TTD)
MonthsArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
QLQ-C30: Physical FunctioningNA (20.5 to NA)NA (10.3 to NA)
QLQ-LC13: CoughingNA (NA to NA)NA (NA to NA)
QLQ-LC13: Chest PainNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Hazard ratio (hr): 0.92 · 95% CI 0.642 to 1.330Hazard ratio was based on unstratified Cox regression model including treatment as covariate.
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Hazard ratio (hr): 0.73 · 95% CI 0.473 to 1.123Hazard ratio was based on unstratified Cox regression model including treatment as covariate.
  • Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Hazard ratio (hr): 0.72 · 95% CI 0.485 to 1.057Hazard ratio was based on unstratified Cox regression model including treatment as covariate.

Adverse events

Collected over All-cause mortality is reported from randomization to the end of study (up to 53 months). Adverse events are reported from from the first dose to 30 days after the last dose or final cutoff on December 29, 2023, maximum treatment exposure was 232 weeks for Arm A and 157 weeks for Arm B.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Tislelizumab + Chemotherapy175/227 (77.1%)94/227 (41.4%)226/227 (99.6%)
Arm B: Placebo + Chemotherapy196/230 (85.2%)70/229 (30.6%)228/229 (99.6%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
ThrombocytopeniaBlood and lymphatic system disorders17/22718/229
NeutropeniaBlood and lymphatic system disorders16/2279/229
Neutrophil count decreasedInvestigations5/2273/229
Platelet count decreasedInvestigations5/2275/229
White blood cell count decreasedInvestigations5/2273/229
HyponatraemiaMetabolism and nutrition disorders5/2271/229
Febrile neutropeniaBlood and lymphatic system disorders3/2275/229
PneumoniaInfections and infestations4/2275/229
HaemoptysisRespiratory, thoracic and mediastinal disorders2/2275/229
Alanine aminotransferase increasedInvestigations4/2270/229
Most frequent other events
Showing 10 of 78
Most frequent other events
EventArm A: Tislelizumab + ChemotherapyArm B: Placebo + Chemotherapy
AnaemiaBlood and lymphatic system disorders192/227191/229
AlopeciaSkin and subcutaneous tissue disorders180/227182/229
NeutropeniaBlood and lymphatic system disorders149/227157/229
White blood cell count decreasedInvestigations126/227147/229
ThrombocytopeniaBlood and lymphatic system disorders108/227114/229
NauseaGastrointestinal disorders101/227100/229
Decreased appetiteMetabolism and nutrition disorders88/22786/229
ConstipationGastrointestinal disorders84/22758/229
LeukopeniaBlood and lymphatic system disorders74/22755/229
Alanine aminotransferase increasedInvestigations67/22746/229

Baseline characteristics

The Intent-to-Treat Analysis Set included all randomized participants.

Age, Continuous
Age, Continuous(years)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Mean61.5 ± 7.7560.7 ± 8.2561.1 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Female414485
Male186186372
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Asian227230457
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(Participants)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
0353469
1192196388
Brain Metastases
Brain Metastases(Participants)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Yes145
No226226452
Chemotherapy
Chemotherapy(Participants)Arm A: Tislelizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Cisplatin474996
Carboplatin180181361
08

Study locations

50 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • China Japan Friendship Hospital
    Beijing, Beijing 100029, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Beijing Hospital
    Beijing, Beijing 100730, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Peking University International Hospital
    Beijing, Beijing 102206, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing 400042, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Wuhan Central Hospital
    Wuhan, Hubei 430014, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • General Hospital of Eastern Theater Command
    Nanjing, Jiangsu 210002, China
  • Nanjing Chest Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shaanxi Provincial Cancer Hospital
    Xian, Shaanxi 710061, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shaanxi 710061, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • The Affiliated Hospital of Qingdao University Branch South
    Qingdao, Shandong 266000, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
  • Sichuan Cancer Hospital and Institute
    Chengdu, Sichuan 610041, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830000, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, Yu Y, Zhang Y, Zhao J, Qin T, Chen C, Leaw S, Zheng W, Song Y; RATIONALE-312 Study Group. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024 Jul;19(7):1073-1085. doi: 10.1016/j.jtho.2024.03.008. Epub 2024 Mar 7. PubMed 38460751 ↗
  • Wu J, Zhang A, Li L, Liu S, Yang F, Yang R. Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer. Clin Ther. 2021 Mar;43(3):582-593.e2. doi: 10.1016/j.clinthera.2020.12.017. Epub 2021 Jan 25. PubMed 33509647 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Apr 2023, 44 months.

Results were first posted in Feb 2025, 1 year 10 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 2, 2019
StartActual
Jul 22, 2019
Primary completionActual
Apr 19, 2023
CompletionActual
Dec 29, 2023
Results first posted
Feb 28, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04005716
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Jul 22, 2019
Primary completion
Apr 19, 2023
Completion
Dec 29, 2023
Results posted
Feb 28, 2025
Last update
Feb 28, 2025

Study contacts

Study Director
study director · Study Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion